Next Article in Journal
Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review
Next Article in Special Issue
GSTO1*CC Genotype (rs4925) Predicts Shorter Survival in Clear Cell Renal Cell Carcinoma Male Patients
Previous Article in Journal
JAK2 Inhibition Impairs Proliferation and Sensitises Cervical Cancer Cells to Cisplatin-Induced Cell Death
Previous Article in Special Issue
MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9
 
 
Review
Peer-Review Record

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

Cancers 2019, 11(12), 1935; https://doi.org/10.3390/cancers11121935
by Nicole Brighi 1, Alberto Farolfi 1,*, Vincenza Conteduca 1, Giorgia Gurioli 2, Stefania Gargiulo 2, Valentina Gallà 3, Giuseppe Schepisi 1, Cristian Lolli 1, Chiara Casadei 1 and Ugo De Giorgi 1
Reviewer 1: Anonymous
Reviewer 2:
Cancers 2019, 11(12), 1935; https://doi.org/10.3390/cancers11121935
Submission received: 4 November 2019 / Revised: 30 November 2019 / Accepted: 1 December 2019 / Published: 4 December 2019
(This article belongs to the Special Issue Renal Cell Carcinoma)

Round 1

Reviewer 1 Report

The authors extensively review the issue of immunotherapy in renal cell carcinoma. The manuscript is well written and well organized.

I would suggest to add a table summarizing the several clones of PD-L1 with the different cut-off used in each study mentioned by the authors. This would help a better undestanding of the usefulness of PD-L1 as predictive marker.

I would suggest to add a paragraph discussing the role of immunotherapy in the main histotypes.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Well written review.

The authors discussed the inflammation in the aspect of prognostic or predictive aspect. Because there are drugs for inflammation such as NSAIDS or anti-IL-1b (canakinumab). Is it possible to comment on the role of these agents for the treatment of RCC?

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop